Printer Friendly

Semcon reports on board proposals of nominations committee.

M2 EQUITYBITES-March 19, 2019-Semcon reports on board proposals of nominations committee


Semcon AB (STO:SEMC), a technology company that develops products based on human needs and behaviour, announced on Monday that its nominations committee has proposed Carl Backman and Eva Elmsted as new members of the board of directors of the company, to the Annual General Meeting 2019 to be held on 24 April 2019.

Also, the nominations committee has proposed re-election of Tore Bertilsson as chairman of the board and the re-election of board members Jeanette Reuterskiold and Karl Thedeen. Reportedly, Marianne Brismar and Jan-Erik Karlsson have declined re-election.

Currently, Backman is CEO of JCE Group Aktiebolag. He is former investment director of Fouriertransform AB and former CEO of Bure Equity AB. He is also chairman of Bruks Siwertell Group AB and Consafe Logistics AB.

Elmstedt is the former EVP Global Services at Nokia Networks and Nokia Siemens Networks. She has earlier held leading positions at Ericsson, 3 and Semcon. She is also chairman of Proact IT Group AB and a board member of

Addtech AB, Gunnebo Group AB, Thule Group AB, Arjo AB and Axiell Group AB.

Semcon's nominations committee's member are Ulf Gillberg, of JCE Group Aktiebolag and chairman of the nominations committee; Mats Andersson, of Nordea Investment Funds; Faruk Tairi, of Europea i Malmo and Tore Bertilsson, the chairman of the board and a co -opted member.

Together, these members represented 37.9% of the votes associated with all the shares in the company as of 31 August 2018.

((Comments on this story may be sent to

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Mar 19, 2019
Previous Article:Alma Media reports on conveyance of shares under long term incentive programme.
Next Article:Innovent doses first malignant tumour patient in Phase I clinical trial of anti-CD47 monoclonal antibody in the US.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |